Startup | October 15, 2021
AUM Biosciences closes US $ 27 million `Series A’ funding round
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
_256_384.jpg)
It works by collecting aerosols and identifies the presence of dangerous pathogens using sensitive, specific and rapid detection in near-real time without laboratory analysis
The state-of-the-art facility provides a pathway from development to large-scale biologics production
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
Lifebit's accompanying suite of AI-powered end-to-end software solutions provide faster data insights, accelerate drug discovery pipelines, and improve clinical trials success
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
The company does not expect the outcome of this inspection to impact its plans
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Emergency Use Authorisation (EUA) is granted for individuals 65 years of age and older, and individuals ages 18 through 64 within certain high-risk groups
Subscribe To Our Newsletter & Stay Updated
